Common Contracts
127 similar null contracts by ZyVersa Therapeutics, Inc., Nxu, Inc., Aptevo Therapeutics Inc., others
NeuroSense Therapeutics Ltd. Attention: Alon Ben-Noon Building BNeuroSense Therapeutics Ltd. • April 12th, 2024 • Pharmaceutical preparations • New York
ContractMatinas BioPharma Holdings, Inc. • April 5th, 2024 • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with th
ContractSpire Global, Inc. • March 21st, 2024 • Communications services, nec • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Spire Global, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”) and greenshoe warrants (the “Greenshoe Warrants”) to purchase shares of Common Stock. The Shares and Greenshoe Warrants shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-267413), which was declared effective by the U.S. Securities and Exchange Commission on September 26, 2022 (the “Registration Statement”). The Shares and Greenshoe Warrants actually placed by the Placement Agent are referred to herein as the “Placement
ContractSELLAS Life Sciences Group, Inc. • March 15th, 2024 • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
Safe & Green Holdings Corp.Safe & Green Holdings Corp. • February 6th, 2024 • Wholesale-lumber & other construction materials • New York
Safe & Green Holdings Corp.Safe & Green Holdings Corp. • January 26th, 2024 • Wholesale-lumber & other construction materials • New York
Myomo, Inc.Myomo, Inc. • January 17th, 2024 • Orthopedic, prosthetic & surgical appliances & supplies • New York
ContractSELLAS Life Sciences Group, Inc. • January 8th, 2024 • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • December 11th, 2023 • Pharmaceutical preparations • New York
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • December 6th, 2023 • Pharmaceutical preparations • New York
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • November 21st, 2023 • Pharmaceutical preparations • New York
ContractZivo Bioscience, Inc. • November 1st, 2023 • Biological products, (no disgnostic substances) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Zivo Bioscience, Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of C
Versus Systems Inc.Versus Systems Inc. • October 17th, 2023 • Services-computer processing & data preparation • New York
September 21, 2023 Neptune Wellness Solutions Inc.Neptune Wellness Solutions Inc. • September 27th, 2023 • Pharmaceutical preparations • New York
Vaccinex, Inc. Attention: Mr. Maurice Zauderer, Ph.D.Vaccinex, Inc. • September 26th, 2023 • Pharmaceutical preparations • New York
Flora Growth Corp.Flora Growth Corp. • September 21st, 2023 • Pharmaceutical preparations • New York
Myomo, Inc.Myomo, Inc. • August 28th, 2023 • Orthopedic, prosthetic & surgical appliances & supplies • New York
Contract180 Life Sciences Corp. • August 15th, 2023 • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and 180 Life Sciences Corp., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares
Aptevo Therapeutics Inc.Aptevo Therapeutics Inc. • August 7th, 2023 • Pharmaceutical preparations • New York
Nxu, Inc.Nxu, Inc. • August 4th, 2023 • Truck & bus bodies • New York
Nxu, Inc.Nxu, Inc. • August 1st, 2023 • Truck & bus bodies • New York
Celularity Inc.Celularity Inc • July 28th, 2023 • Pharmaceutical preparations • New York
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • July 26th, 2023 • Pharmaceutical preparations • New York
Aptevo Therapeutics Inc.Aptevo Therapeutics Inc. • July 14th, 2023 • Pharmaceutical preparations • New York
Nxu, Inc.Nxu, Inc. • July 10th, 2023 • Truck & bus bodies • New York
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • July 7th, 2023 • Pharmaceutical preparations • New York
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • June 30th, 2023 • Pharmaceutical preparations • New York
NeuroSense Therapeutics Ltd. Attention: Alon Ben-Noon Building B 11 HaMenofim Street Herzliya 4672562 Dear Mr. Ben-NoonNeuroSense Therapeutics Ltd. • June 23rd, 2023 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best-efforts” basis, in connection with the proposed placement (the “Placement”) of (i) ordinary shares (the “Shares”) of the Company, no par value (the “Ordinary Shares”), (ii) warrants to purchase Ordinary Shares (the “Warrants”) and (iii) pre-funded warrants to purchase Ordinary Shares (the “Pre-Funded Warrants” and together with the Ordinary Shares and Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein constitute
Versus Systems Inc.Versus Systems Inc. • June 21st, 2023 • Services-computer processing & data preparation • New York
Precision Optics Corporation, Inc. Attn: Joseph N. Forkey, President and TreasurerPrecision Optics Corporation, Inc. • June 20th, 2023 • Electromedical & electrotherapeutic apparatus • New York
June 5, 2023 AgEagle Aerial Systems Inc.AgEagle Aerial Systems Inc. • June 6th, 2023 • Aircraft • New York
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Attn: David P. Luci President and Chief Executive OfficerAcurx Pharmaceuticals, Inc. • May 17th, 2023 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of the Company’s shares of Common Stock, par value $0.001 per share, (the “Shares”), pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), Series C warrants to purchase shares of Common Stock (the “Series C Warrants”) and Series D warrants to purchase shares of Common Stock (the “Series D Warrants”, collectively with the Series C Warrants, the “Warrants,” and collectively with the Shares and Pre-Funded Warrants, the “Securities”). The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein const
May 10, 2023 Neptune Wellness Solutions Inc.Neptune Wellness Solutions Inc. • May 16th, 2023 • Pharmaceutical preparations • New York
Attn: Chief Executive Officer ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc. • April 18th, 2023 • Pharmaceutical preparations • New York
Athersys, Inc. Attention: Mr. Daniel CamardoAthersys, Inc / New • April 18th, 2023 • Pharmaceutical preparations • New York
